Medpace Holdings Inc vs Ralph Lauren Corp — how do they compare? Medpace Holdings Inc trades at $602 (market cap $16.87B), while Ralph Lauren Corp trades at $368.77 (market cap $21.52B). The key difference: Ralph Lauren Corp is the larger of the two by market cap, and Ralph Lauren Corp pays a 1.11% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Ralph Lauren Corp for 84 Days on average.
| MEDP | RL | |
|---|---|---|
Market Cap | $16.87B | $21.52B |
Volume | 207,570 | 454,217 |
Sector | Health | Consumer Cyclical |
52-Week High | $630.19 | $414.25 |
52-Week Low | $393.42 | $309.29 |
Typical Hold Time | 14 Days | 84 Days |
Enterprise Value | $16.48B | $22.58B |
Dividend Yield | — | 1.11% |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% with neutral technical signals and strong fundamental performance. The stock shows robust profitability with 17.67% net income margin and consistent earnings beats in recent quarters. Recent news highlights institutional activity including CEO stock sales and upcoming Q3 2026 earnings report on October 21, 2026. Technical indicators show mixed signals with RSI neutral and ADX bullish, while support sits at $589 and resistance at $629.
MEDP presents a mixed outlook with strong fundamentals offset by high valuations and insider selling. The 21% buy rating from analysts suggests cautious optimism, with $620.44 price target offering 2.7% upside. Key risks include elevated P/E ratio of 35.5 and recent CEO stock sales totaling over $44 million in September 2026. Positive cash flow projection for 2026 supports growth potential despite current net outflow.
Ralph Lauren (RL) trades at $367.39, down 0.35% with a bearish technical signal despite strong fundamentals. The company demonstrates robust profitability with 70.27% gross margins and 37.54% ROE, while consistently beating earnings estimates. Recent news highlights global expansion through new store openings and AI-driven customer experience enhancements. Cash flow remains positive at $258.80M for 2025, supporting the $1.00 dividend declared for October 2026 payment.
The stock presents a compelling value opportunity with analyst consensus target of $456.67 representing 24% upside. Strong brand positioning and operational efficiency drive growth, though competitive pressures and market volatility pose risks. Institutional sentiment remains bullish with 67% buy ratings, suggesting confidence in the company's luxury market strategy and financial performance trajectory.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →